Alexander Gray: Re-defining early-phase development to explore opportunities for assets
Send us Fan Mail
The Life Science industry is both known for great leaps of innovation on the product side, and conservatism of process and practice on the other side. In this episode we dive into the actual state of innovation on the product side as we speak to Alexander Gray, the Chief Medical Officer of IDEA Pharma.
The innovative potential of phase II trials in Life Sciences today is often lost, since the indication is locked in too early in the process. Instead we speak about how keeping the indication open might allow the asset to drive the research to more favorable uses.
Especially in…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.